Based on these findings, it is reasonable to assume that COVID-19 may drastically activate the IL-33/ST2 system in a way similar to that observed for other inflammatory markers, directly affecting patients’ outcomes via sST2′s negative cardiovascular impact, such as pro-hypertrophic and pro-apoptotic effects [178,181]. This evidence concerns the gene IL33 and COVID-19.